Stock Analiz

Vertex Pharmaceuticals Inc. / MA (VRTX) stock forecast and price target

Price $538.60 · data as of November 13, 2026

12-month price target

Average target$595.36
Upside / downside+10.5%
Analysts28
ConsensusBuy
Low $350.00Average $595.36High $725.00

Gold marker: average target · white marker: today’s price ($538.60)

Analyst ratings

Strong buy 6Buy 20Hold 5Sell 1Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$18.14−1.4%$13.3B
Next fiscal year
ends December 31, 2027
$19.92+9.8%$14.7B
Next quarter
ends December 31, 2026
$4.10−18.4%$3.5B
Quarter after
ends March 31, 2027
$4.68+4.7%$3.4B

Consensus of the analysts covering Vertex Pharmaceuticals Inc. / MA, updated daily. In the last 30 days 4 estimates were raised and 4 lowered.

Our model vs. Wall Street

Analysts see 10.5% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Vertex Pharmaceuticals Inc. / MA’s intrinsic value about 53% below today’s market value, and it scores 2.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Vertex Pharmaceuticals Inc. / MA stock price target?

The average 12-month target from 28 analysts is $595.36, 10.5% above the current price of $538.60 Targets range from $350.00 to $725.00.

Is Vertex Pharmaceuticals Inc. / MA a buy according to analysts?

The consensus rating is “Buy” (6 strong buy, 20 buy, 5 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.

How much is Vertex Pharmaceuticals Inc. / MA expected to earn?

Analysts expect EPS of $18.14 for the fiscal year ending December 31, 2026 and $19.92 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.